Fosrenol Lanthanum Carbonate 500 mg

Fosrenol is a lanthanum-carbonate phosphate-binding medicine. Its human reference formulation is a chewable tablet; the 500 mg figure describes lanthanum content per tablet, supplied as lanthanum carbonate hydrate.

What a phosphate binder does

The reference ingredient mechanism involves binding dietary phosphate within the digestive tract, reducing the amount absorbed. This is a different role from live-bacteria renal supplements or nutritional amino-acid blends. A human phosphate-binder label is not a veterinary approval for an animal.

Why the 500 mg wording matters

The strength expresses the amount of lanthanum, rather than tablet count or total carbonate-salt weight. Fosrenol chewable tablets and oral powder are separate presentations. Pack counts also differ by market, so identify the exact tablet pack and count with the enquiry.

The chewable-tablet instruction

The referenced human label calls for complete chewing or crushing instead of swallowing the tablets whole. That instruction belongs to the named human formulation. A veterinarian considering extra-label use determines the suitable product and animal-specific instructions.

Compare the clinical purpose, not just the renal category

A renal category can contain products with very different jobs. Phosphate management depends on the clinical plan and monitoring; a phosphate binder should not be added simply because another kidney product is being used. Keep the exact brand and formulation with that discussion.